The serum mannan-binding protein (MBP) is a host defense
Introduction
The mannan-binding protein (MBP), also called mannosebinding protein (MBP) or mannan-binding lectin (MBL) , is a C-type lectin specific for mannose, N-acetylglucosamine, and fucose residues (Kawasaki et al. 1983; Kawasaki 1999; Takahashi et al. 2005; Dommett et al. 2006; Taylor and Drickamer 2007) . MBP is an important serum component associated with innate immunity (Kawasaki et al. 1989; Super et al. 1989; Hoffmann et al. 1999) . MBP activates complement when it binds to oligosaccharide ligands on the surface of microorganisms (Ikeda et al. 1987 ). This pathway is called the lectin pathway (Malhotra et al. 1994) . The most important property of this host defense system is the distinction between host cells and microorganisms based on the nature of their cell surface carbohydrates. MBP binds to mannooligosaccharide structures on the surfaces of microorganisms, whereas most mammalian cells are covered with complex oligosaccharides with sialic acids at their nonreducing termini, which precludes the binding of MBP to the cells. However, we and others previously noticed that MBP binds to some human tumor cell lines, suggesting the possibility that MBP also functions as a defense factor against abnormal cells produced in host animals (Ohta and Kawasaki 1994; Muto et al. 1999 ). In the following study, we found that the vaccinia virus carrying the human MBP gene exhibited potent growth inhibitory activity toward human colorectal carcinoma, SW1116, cells in nude mice via a complement-independent mechanism (Ma et al. 1999) . We have proposed calling this activity MBPdependent cell-mediated cytotoxicity (MDCC).
In our previous study, we isolated and characterized the endogenous MBP-ligand oligosaccharides (MLO) expressed on SW1116 cells, which were assumed to be associated with MDCC (Terada et al. 2005) . The MLO on SW1116 cells were N-glycans with highly fucosylated polylactosamine-type structures and large molecular sizes. At their nonreducing termini, Le b -Le a or tandem repeats of the Le a structure prevailed, a substantial proportion of which were attached via internal Le x or N-acetyllactosamine units to the trimannosyl fucosylated core. This novel structure may represent a new type of tumorassociated carbohydrate antigen.
In this study, we attempted to identify and characterize the glycoproteins carrying the MLO with the unique structure. By using an MBP-affinity column, two major MBP-ligand glycoproteins (MLGPs) were isolated and identified as CD26 (dipeptidyl peptidase IV (DPPIV)) and CD98 heavy chain (CD98hc). The digestion of these MLGPs with PNGase F and endo-β-N-acetylglucosaminidase H (endo H) indicated that the N Kawasaki et al.
Fig. 1.
Isolation of cell surface glycoproteins carrying MBP ligands from SW1116 cells and their susceptibility to glycosidase digestion. SW1116 cells were surface-labeled with sulfo-NHS-biotin and lysed in 1.0% Nonidet P-40-containing buffer, and then the lysates were applied to an MBP column. The eluate with the EDTA-containing buffer from the MBP column was then applied to an immobilized monomeric avidin column, as described under Material and methods. Then, the biotinylated MBP-ligand glycoproteins were analyzed for susceptibility to glycosidase digestion for 18 h at 37 • C with PNGase F or endo H. After deglycosylation treatment, the control (no enzyme) and enzyme-treated proteins were applied to a second MBP-affinity column. Each sample before application to the second MBP column, and the pass-through and eluated fractions were resolved by SDS-PAGE on a 5-20% gradient gel under reducing conditions. The labeled proteins were transferred to a nitrocellulose membrane, and then detected with horseradish peroxidase-conjugated streptavidin. Lanes 1-3, samples without glycosidase digestion; lanes 4-6, samples after PNGase F digestion; lanes 7-9, samples after endo H digestion. Lanes 1, 4, and 7, an aliquot before application to the second MBP column; lanes 2, 5, and 8, pass-through fraction from the second MBP column; lanes 3, 6, and 9, eluated fraction from the second MBP column. Lane M, molecular weight markers.
characteristic MLO was attached to CD26. Chymotryptic digests of CD26 were fractionated into MBP-binding glycopeptides and non-MBP-binding glycopeptides. Subsequent structural analysis of these two glycopeptide fractions demonstrated that complex-type N-glycans with larger than four Fuc(HexHexNAc) units are critical for the high affinity binding to MBP.
Results

Characterization of cell surface MBP-ligand glycoproteins
The cell surface glycoprotein fraction that contained MBP ligands was isolated from SW1116 cells, which had been labeled using sulfo-NHS-biotin, by means of an MBP-affinity column followed by a monomeric avidin-affinity column. Upon SDS-PAGE under reducing conditions, the fraction was shown to contain one major protein band of 110 kDa and a couple of minor protein bands, which were detected after visualization by a chemiluminescence staining method using horseradish peroxidase-conjugated streptavidin (see Figure 1 , lane 1). All these proteins were recovered in the eluated fraction of the second MBP column (lane 3), and no visible protein was recovered in the pass-through fraction (lane 2) as was expected. After PNGase F digestion, the molecular size of the major protein band was significantly reduced (lane 4), and most of the proteins were recovered in the pass-through fraction (lane 5), indicating that they lost the binding activity to an MBP column almost completely. In contrast, after endo H digestion, no significant change was generated in their protein profiles (lane 1 versus lane 7), and all proteins retained their MBP-binding activity as evidenced by the absence of protein bands in lane 8 and the close resemblance of the protein profiles between lane 7 and lane 9. These experiments demonstrated clearly that the cell surface MLGPs consisted mainly of complex-type N-glycans and not of high-mannose-type or hybrid-type N-glycans. However, it may be worthy of note that a broad protein band of around 80 kDa was detected in lane 6 (the eluated fraction of the second MBP column), inferring the presence of PNGase F-resistant MBP-binding components such as mucin-type glycoproteins. In fact, our preliminary experiments indicated that the MBP-binding activity of the SW1116 cells analyzed by flow cytometry using FITC-labeled MBP was reduced significantly by the pretreatment of the cells with benzyl-2-acetamide-2-deoxy-α-galactopyranoside (Bz−α-GalNAc), an inhibitor of O-glycan biosynthesis (Huang et al. 1992 ) (data not shown).
Isolation and identification of MBP-ligand glycoproteins from SW1116 cell lysates
In order to identify the carrier proteins of the MLO having the unique structure, SW1116 cell lysates were applied to an AAL (Aleuria aurantia lectin)-agarose column, which binds the Fucα1-6 structure most preferentially followed by the Fucα1-2 and Fucα1-3 structures (Yamashita et al. 1985) , and subsequently to an anti-Le b mAb-Sepharose 4B column and an MBPSepharose 4B column. The proteins bound to the MBP column in the presence of calcium were eluted with EDTA, and then resolved by SDS-PAGE under reducing conditions. As shown in Figure 2A , two major protein bands were observed. LC-MS/MS analysis of the in-gel trypsin digests of these two bands indicated that the 110 kDa protein was CD26/dipeptidyl peptidase IV (DPPIV) and the 82 kDa protein was CD98 heavy chain (CD98hc)/4F2hc. The amino acid sequences corresponding to those of the respective proteins are shown in red in Figure 2B . CD26 and CD98hc are proteins that have nine and four potential N-glycosylation sites, respectively, as shown by yellow-shaded areas in their primary sequences.
MBP-binding activity of MBP-ligand glycoproteins after glycosidase digestion
The properties of the oligosaccharides attached to these glycoproteins were examined by means of glycosidase digestion and MBP lectin blot. Upon PNGase F digestion, the CD26 protein band (110 kDa) disappeared almost completely and a new band appeared at around 85 kDa, while the molecular size of CD98hc did not change significantly (data not shown). On the other hand, the MBP-binding activities of both CD26 and CD98hc, as examined by MBP blotting, were completely lost upon PNGase F digestion, as shown in Figure 3A , lane 1 (as compared to lane 2, which is without PNGase F digestion). In contrast, upon endo H digestion, CD98hc lost the MBPbinding activity almost completely, whereas CD26 retained a significant portion of the MBP-binding activity (lane 3). These results indicated that CD98hc contains high-mannose-type or hybrid-type oligosaccharides, which are responsible for the MBP binding by CD98hc, whereas CD26 appears to contain the target oligosaccharides of the present study, highly fucosylated polylactosamine-type glycans of MBP ligands (MLO) as well as high-mannose-type or hybrid-type oligosaccharides. We also examined the protein profiles of CD26 and CD98hc before and after endo H digestion in order to obtain structural information accompanied with the reduction of the MBP-binding activity. However, the observed shifts in the respective molecular sizes of CD26 and CD98hc after endo H digestion were not so significant (data not shown) that it is difficult to explore this problem further at present.
MALDI-MS mapping of the permethylated N-glycans released in-gel from CD26
To ascertain if CD26 carries the unique MBP ligands (MLO) comprising multimeric Le a /Le b , its N-glycans were released in-gel with PNGase F for MS analyses from the single protein band ( Figure 3B ) corresponding to CD26 isolated consecutively with AAL-, MBP-, and anti-human CD26 mAb affinity columns from SW1116 cell lysates. As shown in Figure 4A , the major molecular ion signals observed on MALDI-MS analysis of the permethylated N-glycans correspond to [M+Na] + of a hybridtype N-glycans with 1 Fuc(Hex-HexNAc) terminal, followed by complex-type N-glycans with 2 Fuc(Hex-HexNAc) termini, and go up by multiples (up to 6) of Fuc(Hex-HexNAc) increments, as annotated. Composition-wise, the majority of the signals appear to also reflect core fucosylation and a bisecting GlcNAc, while a small amount was further sialylated. Additional high-mannosetype N-glycans (Man5-Man7) were also detected. More importantly, the overall profile is fully consistent with a subset of the CD26 N-glycans carrying the requisite MLO as isolated and defined previously from SW1116 cell lysates (Terada et al. 2005) , the removal of which by PNGase F would lead to the loss of MBP binding ( Figure 3A , lane 1). Given the size and structural heterogeneity, it could also be predicted that the smaller biand triantennary N-glycans would not constitute high affinity MLO despite the similar presence of Fuc(Hex-HexNAc) terminal epitopes, and that not all N-glycosylation sites may contribute equally to MBP binding. To substantiate this, it would be of interest to determine which glycopeptides would be recovered in the MBP-binding and non-MBP-binding fractions, respectively.
Analysis of MBP-binding and non-MBP-binding glycopeptides from chymotryptic digests of CD26
The extreme heterogeneity and large size of the MLO imposed a significant technical challenge as to the detection and identification directly of the intact glycopeptides by MS analyses. In a pilot experiment, it was found that the chymotrypsin-digested products derived from the 3 H-glucosamine-labeled CD26 afforded a better recovery (88%) of the radioactivity on an MBP column, where the radioactivities distributed in the pass-through and binding fractions were 72% and 28%, respectively. For subsequent studies, the MBP-binding and non-MBP-binding glycopeptides were therefore prepared from chymotrypsin digests of the cold CD26 sample, instead of the more commonly used trypsin. After desalting, the N-glycans and de-N-glycosylated peptides were analyzed by MS separately. At first glance, the N-glycan profile of the non-MBP-binding fraction ( Figure 4B ) resembles that of the total N-glycans derived from in-gel digested CD26 ( Figure 4A ), whereas no significant N-glycan N Kawasaki et al. and MBP-affinity columns, were analyzed for susceptibility to glycosidase digestion by treatment with PNGase F or endo H at 37 • C for 18 h. After deglycosylation treatment, the control and treated proteins were resolved by SDS-PAGE on a 5-20% gradient gel under reducing conditions, and then the proteins were transferred to a nitrocellulose membrane, followed by MBP lectin-blot detection as described under Material and methods. MBP blotting after treatment of the MBP-ligand glycoproteins in the presence (+) and absence (−) of PNGase F (lanes 1 and 2) or endo H (lanes 3 and 4). The filled arrowhead indicated the position of the CD26 band and open arrowhead CD98hc. The positions of molecular weight markers are shown in the left margin. (B) CD 26 was isolated using an anti-human CD26 mAb-Sepharose 4B column from the MBP-ligand glycoproteins, which had been isolated with AAL and MBP-affinity columns, and resolved by SDS-PAGE on a 5-20% gradient gel under reducing conditions. The proteins were detected by colloidal Coomassie brilliant blue staining. The arrowhead indicates the purified CD26 band (lane 1). Lane M, molecular weight markers.
signal was detected for the sample derived from the MBPbinding fraction (data not shown), when analyzed by MALDI-MS in the reflectron mode. However, closer examination revealed that the signal intensities of larger complex-type Nglycans, particularly for those above m/z 3800, corresponding to having more than four Fuc(Hex-HexNAc) units, appeared to be significantly lower relative to the one with two Fuc(HexHexNAc) termini (m/z 2837), in the nonbinding fraction. With linear mode MALDI-MS, which is more conducive for detecting species of higher molecular mass, albeit with lower resolution, it is clear that the N-glycan profiles derived from the non-MBP-binding fraction afforded a major signal at m/z 3460, corresponding to having three Fuc(Hex-HexNAc) units, and extended mostly to just above m/z 5000, components carrying a total of four to six Fuc(Hex-HexNAc) units affording only very weak signals ( Figure 5A ). In contrast, the MBP-binding fraction, which did not give any significant N-glycan signals in the reflectron mode, afforded major signals above m/z 3900, corresponding to having four Fuc(Hex-HexNAc) units, and extending up to about m/z 6400, corresponding to having five to seven Fuc(HexHexNAc) units ( Figure 5B ). This striking pattern demonstrated clearly that glycopeptides from CD26 that could bind efficiently to an MBP column carried mostly complex-type N-glycans with at least four Fuc(Hex-HexNAc) units. As a consequence of these larger glycopeptides being preferentially enriched in the binding fraction, the nonbinding fraction in turn contained less of these relative to those smaller ones. Conversely, the glycopeptides with bi-and tri-antennary complex-type N-glycans were found mostly in the nonbinding fraction. It should be further noted that glycopeptides carrying high-mannose structures were also clearly not MLO as these glycans were likewise prominently detected only in the nonbinding fraction.
To identify the respective glycosylation sites represented by the glycopeptides in the binding and nonbinding fractions, the de-N-glycosylated peptides were subjected to automated nanoLC-ESI-MS/MS analyses, and the resulting MS/MS data were matched against the CD26 protein sequence by means of Mascot search, as well as by further manual interpretation of the de novo sequencing data. Through the latter process, it was found that peptide matching or coverage was substantially improved by not specifying chymotrypsin in the database search. This was due to an unexpectedly high degree of nonspecific cleavage induced by chymotrypsin and the lengthy isolation procedure employed. Furthermore, it was found that most peptides were additionally modified at their N-termini through carbamylation, most likely due to the use of urea in the digestion, which produced isocyanic acid that would react with primary amine groups. Taking these factors into consideration for the search criteria and manual data interpretation, peptides encompassing seven out of nine potential N-glycosylation sites were identified in the nonbinding fractions ( Figure 6 ). The PNGase F-treated peptides carrying these NXS/T sites all exhibited conversion of Asn to Asp, with a mass increment of one unit, thus suggesting that all these seven sites (N85, 92, 150, 229, 281, 520, and 685) were originally N-glycosylated since the Asn residue at a nonoccupied site would remain as such. The two other sites at N219 and N321 were not identified, which was most likely due to their being too small in size to be detected via LC-MS/MS or they might have been lost in the first place on the Sephadex G-10 column used for desalting. Similar LC-MS/MS analysis of the binding fraction followed by an MS/MS ion search using the same criteria as described above (carbamylation, nonspecific cleavage, and Asn to Asp conversion) led to unambiguous identification of five N-glycosylated sites (N85, 92, 150, 229, and 685). The two sites at N281 and N520, which could be identified in the nonbinding fraction, were not detected in the binding fraction, whereas the two sites at N219 and N321 were not detected in either fraction. Since the chymotryptic peptide carrying N520 gave a good MS response and good quality MS/MS data for the non-MBP-binding fraction, it may be inferred that it indeed did not carry high affinity MBP ligands and therefore could not be found in the MBP-binding fraction, which would otherwise be readily detected. Overall, it may be concluded that most glycosylation sites (at least five out of the seven identified) are equally heterogeneous in their N-glycosylation profile, comprising both MBP ligands and nonligand glycoforms at variable proportions. The site at N520, for example, may carry mostly smaller, non-MBP-binding The N-glycan profile of the nonbinding glycopeptide fraction resembles the total N-glycan profile of the CD26 but is notably cleaner with more prominent signals corresponding to high-mannose-type structures. When also analyzed in the reflectron mode, the bound glycopeptide fraction did not afford any meaningful N-glycan signals (data not shown). The major sodiated molecular ion series could be assigned as core fucosylated, bisected complex-type N-glycans with 2-6 Fuc(Hex-HexNAc) units based on the molecular composition and previously characterized structures for MBP ligands (Terada et al. 2005) , as annotated. Each is accompanied by an additional degree of fucosylation ( ). Heterogeneity also arises from the lack of the extra bisecting GlcNAc () and/or additional sialylation ( ). (᭺, ) Represents Hex (Gal, Man). For simplicity and to avoid overcrowded annotation, not all signals are annotated.
N-glycans because the majority of these were not retained by the MBP column.
The three-dimensional structure of the extracellular domain (39-766) of human CD26 (type II transmembrane, glycosylated), which was produced using a recombinant baculovirus system, is shown in Figure 7 , being cited from K Aertgeerts et al. (2004) with modification. Seven (N229, N150, N281, N219, N92, N85, and N321) of the nine potential N-glycosylation sites were in the propeller domain of the molecule (blue), and two sites (N685 and N520) were in the hydrolase domain (red). Seven sites (N685 and N520 in the hydrolase domain and N229, N150, N281, N92, and N85 in the propeller domain) were found to be glycosylated but two sites, N321 and N219 (indicated by gray circles), were not identified. It should be noted that N281 and N520 (green circles) were found in the nonbinding fraction but not in the binding fraction, and the other sites that were marked doubly by green and pink circles were found not only in the binding fraction but also in the nonbinding fraction.
Model structure of the MBP-Lewis oligosaccharides complex
The observations that the MBP column binding glycopeptides carried mostly complex-type N-glycans with at least four Fuc(Hex-HexNAc) units while the nonbinding fraction in turn contained N-glycans with two or three Fuc(Hex-HexNAc) units and the ones with high-mannose structures suggested the possibility that four Fuc(Hex-HexNAc) units may have a certain unique conformation preferable for the high affinity binding to MBP. In accordance with this hypothesis, computer modeling suggested the possibility that the tandem repeat structure of the Le a unit can form a right-handed helix in which equivalent positions recur every eight Le a units, as shown in Figure 8A . In addition, viewing the Le a α helix from the top, we find that fucose residues extend away from the long axis of the chain and every fourth fucose residue recurs at an equivalent position ( Figure 8B ). This unique topology of fucose residues in the Le a α helix may be relevant to the high affinity binding of these ligands to MBP. Figure 12 in Terada et al. 2005) . Of the two fucose residues in the Le b unit, the one in the Le a unit appears to contribute to the protein binding, and the other fucose residue on the penultimate Le a unit feasibly interacts with Lys183 and Asp184 on the MBP molecule ( Figure 9B ). The binding of each oligosaccharide chain at the trimeric protein structure resulted in the formation of a bundle of three oligosaccharide chains with fucose-fucose and galactose-galactose interactions in the three Le a units at the Le x end. Since the bundle formation occurred at the Le a unit at the Le x end, the five tandem structures of the Le a units (or four Le a and one Le b units) appear to be important for the bundle formation. A short model with the reduction of the number of the Le a moieties did not allow the formation of the trimeric oligosaccharide bundle.
Discussion
In this study, a human colon cancer glycoprotein, which carries the endogenous ligands for serum lectin MBP, was identified as CD26 (DPPIV). We previously elucidated the characteristic structures of the endogenous oligosaccharide ligands for MBP on SW1116 cells. The MBP-oligosaccharides have the Le b /Le a structure or tandem repeats of the Le a structure at their nonreducing termini (Terada et al. 2005) . The cell surface labeling experiment indicated that the major MBP-binding glycoprotein on the surface of SW1116 cells was a 110 kDa protein, which was later identified as CD26. MALDI-MS analysis of the Nglycans released from the purified CD26 clearly showed the presence of unique MLO on the CD26 molecule. Initially, we assumed that all the N-glycans on the CD26 molecule bound to an MBP column, but this was not really the case. These results, however, provided us an opportunity to study the mode of carbohydrate recognition of MBP by comparing the structures of the MBP-binding glycans with those of non-MBP-binding glycans isolated from the same molecule, CD26. Intriguingly, the N-glycans released from the non-MBP-binding glycopeptides contained M5-M9 high-mannose-type glycans and complextype glycans mostly smaller than those with three LacNAc units (the term "LacNAc" usually implies type 2, Galβ1-4GlcNAc, whereas in this paper it implies both type 1 and 2 units). In contrast, the N-glycans from MBP-binding glycopeptides contained complex-type glycans with more than four LacNAc units. These results are completely consistent with our previous finding that MLO comprises 5 to 13 LacNAc units (see Figure 3 in Terada et al. 2005) . It was also shown in our previous report that the binding affinity of carbohydrate ligands to MBP depends markedly on the clustering or topological pattern of the ligand sugars. Such sequence may be those in which every one of the four Le a /Le b units binds to trimannosyl core to make tetraantennary N-glycans and/or Le a /Le b units present as tandem repeat on either antenna of N-glycans. With this regard, it is worthy of note that most of the MBP-binding activity of MLO was lost after endo-β-galactosidase digestion, where the distribution of the sizes of the digests was significantly smaller than those of the original MLO, although most of the digested oligosaccharides still bound to an AAL (fucose-binding) column (see Figure 6 in Terada et al. 2005) . Interestingly, 3D-structure modeling indicated the unique topology of fucose residues in the Le a α helix, which may be relevant to the high affinity binding of these ligands to MBP. In addition, the binding of each MLO chain at the trimeric protein structure of CRD of MBP resulted in the formation of a bundle of three oligosaccharide chains. These results are consistent with the view that host defense molecules associated with innate immunity like MBP recognize specific topological patterns generated by the ligand molecules. However, it is clear that elucidation of the precise mechanisms of MBP recognition requires further studies by NMR or X-ray crystallography using synthetic ligands, and the study along these lines is now in progress. With respect to the MBP recognition of the oligo-LacNAc units, we also studied the interaction between MBP and glycolipids with Le a trisaccharide units (1-3) on the lactosylceramides, which were isolated and characterized from COLO205 cells very recently (Fan et al. 2008 CD26 is a 110 kDa cell surface glycoprotein expressed on various tissues, including epithelial cells of liver, intestine, and kidney and is involved in tumor development of certain human cancers (Iwata and Morimoto 1999; Pro and Dang 2004; Havre et al. 2008) . Inamoto et al. (2007) recently reported that CD26 is highly expressed on the cell surface of malignant mesotheliomas and that a newly developed humanized anti-CD26 monoclonal antibody has an inhibitory effect on malignant mesothelioma cells both in vivo and in vitro via antibody-dependent cellmediated cytotoxicity in addition to its direct anti-tumor effect. They also described that the anti-CD26 monoclonal antibody inhibits the growth of human renal carcinoma cells both in vitro and in vivo. Meanwhile, they found that the murine anti-CD26 mAb 14D10, from which the humanized anti-CD26 monoclonal antibody was constructed, recognized the cell membraneproximal glycosylated region and has a direct anti-tumor effect by inducing G1-S arrest while concomitantly blocking the adhesion of cancer cells to the ECM. With this regard, it may be worthy of note that CD26 mAb 44-4, which was used for the purification of CD26 from SW1116 cell lysates in this study, lost its binding activity to the PNGase F-treated CD26 (data not shown), suggesting that the mAb 44-4 recognized the antigenic determinant containing N-glycans and/or the conformational structure in the vicinity of the N-glycan attachment sites. It may be reasonable to assume that the N-glycans with the unique structures of the Le a epitope tandem repeats expressed on the CD26 molecules may be a molecular target for MBP and play a key role in triggering growth inhibitory activity toward a certain type of colon cancer cells that we call MDCC. Consequently, MBP may have potential clinical use as a novel cancer diagnostic and therapeutic agent for CD26-positive tumors, such as malignant mesotheliomas, CD26-positive T-cell malignancies (Ohnuma et al. 2002) , and renal cell carcinomas (Inamoto (Ohta and Kawasaki 1994; Muto et al. 1999 ) and tissues (unpublished data).
CD26 is known to be a highly glycosylated protein. However, the detailed structures of the N-glycans on the CD26 molecule have been little elucidated. In this study, using MS analyses, the structures of the N-glycans expressed on the CD26 molecule on the surface of human colon cancer cells, SW1116, and the N-glycosylation sites were characterized with respect to the ligands for a lectin, MBP. We have analyzed the distribution of the glycosylation sites between the non-MBP-binding and MBPbinding glycopeptides by means of the glycoproteomic-type approach. We could assign seven out of the total nine possible N-glycosylation sites in CD26. Two sites, N281 and N520, were found only in the MBP-non-binding glycopeptides, i.e., not in the MBP-binding fraction. Thus, these two sites probably do not carry MBP ligands. We may say that N281 and N520 were preferentially modified to Man5-7, simple hybridtype or biantennary complex-type. Enzyme systems that synthesize MBP ligands (e.g., β3-galactosyltransferase (Fan et al. 2008) ) disfavor N281 and N520 for some reason. However, five of the seven N-glycosylation sites identified, N85, N95, N150, N229, and N685, were recovered both in the MBP-nonbinding and MBP-binding fractions. These results indicated that the unique MBP ligands were expressed preferentially at some potential N-glycosylation sites but this site preference was not so stringent.
From the crystal structure of the extracellular domain (39-766) of human CD26 (type II transmembrane, glycosylated) produced using a recombinant baculovirus system (Figure 7) , it has been inferred that all nine potential N-glycosylation sites are occupied based on the calculated electron-density maps (Aertgeerts et al. 2004 ). We do not know whether the two remaining potential N-glycosylation sites of the nine sites, namely N219 and N321, were glycosylated or not since these two peptides were not detected in either the MBP-binding or non-MBPbinding fraction. A possible cause is that the corresponding chymotryptic peptides may have been too short, especially if they are not glycosylated and/or with the extra nonspecific cleavages generally observed, for them to be efficiently recovered and detected. We prepared the chymotrypsin digested glycopeptides and peptides for MS analysis in this study based on the results of a pilot experiment involving a CD26 sample metabolically labeled with 3 H-glucosamine. In contrast with chymotrypsin digestion, the yields of trypsin digestion obtained from the starting amount through the steps before application to an MBP column were found not to be good and about half the peptides (and glycopeptides) seemed to become insoluble on trypsin digestion for some reason, and the recovery of the radioactivity on an MBP column was quite low (40%). Thus, glycopeptide preparation through CD26 tryptic digest was very difficult and unsuitable for the CD26.
The proteomic analysis of the MBP-binding glycoprotein fraction isolated from the SW1116 cell lysates suggested that the CD98 heavy chain (CD98hc), which had four potential N-glycosylation sites, might also carry MLO. However, the MBP-binding activity of CD98hc was abolished almost completely by endo H digestion, excluding the possibility that highly fucosylated polylactosamine-type structures are expressed on CD98hc and suggesting that high-mannose-type or hybrid-type oligosaccharides are associated with the MBP-binding activity. Since all glycoproteins carrying high-mannose-type oligosaccharides are not always good ligands for MBP, it is possible that CD98hc high-mannose-type oligosaccharides bind to MBP just by forming some specific three-dimensional complexes along the CD98 polypeptide backbone. This might also be the case in high-mannose-type glycans in CD26. In any case, CD98hc has also been reported to be related with tumorigenicity (Hara et al. 2000; Esseghir et al. 2006; Asano et al. 2007) .
In summary, the present study demonstrated clearly that the endogenous lectin MBP, which is an important host defense component, binds endogenous ligand oligosaccharides expressed on the CD26 molecule on the surface of colon cancer cells with a characteristic high selectivity. This selectivity stems most probably from the geometric multiplicity of a blood group-type trisaccharide epitope, Le b /Le a , in the ligand oligosaccharides. Chromatography buffers PBS (−) was a 9.6 mM phosphate buffer, pH 7.5, containing 137 mM NaCl and 2.7 mM KCl. HBS was a 50 mM HEPESNaOH buffer, pH 7.5, containing 150 mM NaCl. TBS was a 20 mM Tris-HCl buffer, pH 7.5, containing 150 mM NaCl. TBS# was a 20 mM Tris-HCl buffer, pH 7.5, containing 0.5 M NaCl. IBS was a 20 mM imidazole-HCl buffer, pH 7.8, containing 150 mM NaCl. HBS-N1 was HBS containing 1% Nonidet P-40. HBS-N2 was HBS containing 20 mM CaCl 2 and 0.1% Nonidet P-40. HBS-N3 was HBS containing 2 mM EDTA and 0.1% Nonidet P-40. HBS-N4 was HBS containing 0.1% Nonidet P-40. HBS-N5 was HBS containing 5 mM fucose, 2 mM EDTA, and 0.1% Nonidet-P40. IBS-N was IBS containing 0.1% Nonidet P-40. DEA-N was a 50 mM diethylamine-HCl buffer, pH 11.8, containing 0.1% Nonidet P-40. HBS-C1 was HBS containing 2 mM CHAPS and 20 mM CaCl 2 . HBS-C2 was HBS containing 2 mM CHAPS and 2 mM EDTA. HBS-T1 was HBS containing 1% Triton X-100. HBS-T2 was HBS containing 1% Triton X-100, 5 mM fucose, and 2 mM EDTA. HBS-T3 was HBS containing 20 mM CaCl 2 and 1% Triton X-100. HBS-T4 was HBS containing 2 mM EDTA and 1% Triton X-100. TBS#-T1 was TBS# containing 1% Triton X-100. TBS#-T2 was TBS# containing 0.1% Triton X-100. DEA-T was a 50 mM diethylamine-HCl buffer, pH 11.5, containing 0.5 M NaCl and 0.1% Triton X-100. HBS-1 was HBS containing 20 mM CaCl 2 . HBS-2 was HBS containing 2 mM EDTA. A 2% final concentration of the protease inhibitor mixture (Protease Inhibitor Cocktail for use with mammalian cell and tissue extract), comprising 100 mM PMSF, 80 mM aprotinin (bovine lung), 1.5 mM E-64, 2 mM leupeptin hemisulfate hydrate, 5 mM bestatin, and 1 mM pepstatin, was added to each buffer for the isolation of the cell surface MLGPs from the biotin-labeled cells and the MLGPs from cell lysates, and the purification of CD26 from cell lysates unless otherwise stated.
Material and methods
Materials
Cell culture and preparation of cell lysates from SW1116 cells
The culturing of a human colorectal carcinoma cell line, SW1116, and the preparation of cell lysates were carried out essentially according to the procedures described previously (Terada et al. 2005 ) except that to all buffers a protease inhibitor cocktail was added to a final concentration of 2%. The cell lysates were stored at −80
• C until use.
Preparation of rabbit serum MBP and MBP-Sepharose 4B
Purification of MBP from normal rabbit serum on an affinity column of Sepharose 4B-mannan and coupling of the purified rabbit serum MBP to CNBr-activated Sepharose 4B were carried out according to the methods described previously (Terada et al. 2005) . In this study, MBP-agarose (Pierce-Thermo Fisher Scientific, Inc.) was used as well as MBP-Sepharose 4B.
Preparation of an anti-Le b monoclonal antibody (mAb)-Sepharose 4B
An anti-Le b mAb (clone 2-25 LE, mouse IgG1) was coupled to CNBr-activated Sepharose 4B (2 mg protein per mL of gel) according to the manufacturer's instructions.
Preparations of anti-human CD26 mAb and anti-CD26 mAb-Sepharose 4B
Hybridoma cells producing an anti-human CD26 mAb (clone 44-4, mouse IgG1) were provided by the Department of Laboratory Medicine, Faculty of Medicine, University of Miyazaki. The anti-human CD26 mAb was purified from BALB/c mice ascites by ammonium sulfate precipitation, followed by chromatography on a protein G column. The purified anti-human CD26 mAb was coupled to CNBr-activated Sepharose 4B (3 mg protein per mL of gel).
Metabolic labeling of SW1116 cells with
3 H-glucosamine In the pilot experiments for the monitoring of the glycopeptides prepared from the purified CD26, SW1116 cells were metabolically labeled with D-[1- 3 H]glucosamine hydrochloride according to the procedure described previously (Terada et al. 2005) . 3 H-labeled SW1116 cell lysates were prepared according to the procedures used for the preparation of the non-labeled cell lysates.
CD26: the unique MBP-ligand oligosaccharides carrier on SW1116 cells
Cell surface labeling and preparation of surface-labeled cell lysates SW1116 cells (1-3 × 10 7 cells/75 cm 2 flask) were washed twice with PBS (−) containing 2 mM EDTA and once with PBS (−), and then incubated in 1 mg/mL sulfo-NHS-biotin in PBS (−) at 4
• C for 45 min with gentle shaking. The reaction was stopped by the addition of PBS (−) containing 20 mM glycine (pH 7.4) to the cells. After washing the cells with PBS (−), and then with HBS, the cells were lysed by gentle shaking for 30 min at 4
• C in HBS-N1. Nuclei and insoluble substances were removed by centrifugation at 400 × g for 10 min, and then at 100,000 × g for 30 min at 4
• C, respectively, and the supernatant was saved as the biotin-labeled cell lysates and kept at −80
• C.
Isolation of MBP-ligand cell surface glycoproteins from the biotin-labeled SW1116 cells
To the cell lysates derived from SW1116 cells (11 flasks × 75 cm 2 flask), which had been surface-labeled with biotin, was added an equal volume of double concentration HBS-N2 (a calcium-containing buffer), followed by application to an MBP-affinity column (gel volume; 5 mL) equilibrated with HBS-N2. After the column had been washed with HBS-N2, the bound proteins were eluted with HBS-N3 (an EDTA-containing buffer). The fraction eluted from the MBP column was applied to a monomeric avidin column (gel volume; 5 mL) equilibrated with HBS-N4. The column was washed with HBS-N4, and then bound proteins were eluted with HBS-N4 containing 2 mM Dbiotin. The bound fractions from the monomeric avidin column were resolved by SDS-PAGE on a 5-20% gradient gel, and then transferred to a nitrocellulose membrane. The membrane was treated with TBS containing 3% skim milk. After incubation of the membrane with horseradish peroxidase-conjugated streptavidin for 60 min at room temperature, the surface-biotinylated proteins were visualized with a chemiluminescent substrate kit according to the manufacturer's instructions.
Glycosidase digestion of biotinylated MBP-ligand glycoproteins
The MBP-binding glycoproteins were digested with 1.75 U of PNGase F (Boehringer Mannheim GmbH) or 5 mU of endo H at 37
• C for 18 h in the presence of the protease inhibitor mixture. The samples before and after glycosidase digestions dissolved in HBS-N2 were applied to an MBP-affinity column, and the bound proteins were eluted with HBS-N3. The pass-through and bound fractions were resolved on a 5-20% polyacrylamide gradient gel and visualized with a chemiluminescent substrate kit.
Isolation and identification of glycoproteins carrying MBP-ligand oligosaccharides from SW1116 cell lysates
The cell lysates prepared from 2.5 flasks × 175 cm 2 flask (1 × 10 8 cells) were thawed, and then centrifuged at 10,000 × g for 20 min, and the supernatants were applied to an AAL column (gel volume; 0.5 mL), which had been equilibrated with HBS-N4. The column was washed with HBS-N4, and the bound glycoproteins were eluted with HBS-N5 (a fucose-containing buffer). The fraction bound on an AAL column was applied to an anti-Le b mAb-Sepharose 4B column (gel volume; 0.5 mL), which had been equilibrated with IBS-N. The column was washed with IBS-N, and the bound glycoproteins were eluted with DEA-N (an alkaline buffer). The fractions eluted were immediately neutralized to pH 7.5, CaCl 2 was added to 20 mM, and then the fractions were applied to an MBP column (gel volume; 1 mL), which had been equilibrated with HBS-C1 (a calcium-containing buffer). The column was washed with HBS-C1, and the MBP-binding glycoproteins were eluted with HBS-C2 (an EDTA-containing buffer). The proteins eluted were concentrated by ultrafiltration (10 K membrane), and then resolved on a 5-20% polyacrylamide gradient gel and stained with colloidal Coomassie brilliant blue G-250. Bands were excised from the gel and subjected to in-gel digestion with trypsin. The peptides released from the gel were subjected to liquid chromatography/tandem mass spectrometry (LC-MS/MS) analysis using a hybrid quadrupole/time-of-flight mass spectrometer (Qstar Pulsar I; Applied Biosystems, Foster City, CA) interfaced on line with a capillary HPLC (Paradigm; Michrom BioResources, Inc., Auburn, CA) equipped with a Magic C18 column (0.2 × 50 mm, 3 μm; Michrom BioResources, Inc.). The eluents consisted of water containing 2% acetonitrile and 0.01% formic acid (pump A), and 90% acetonitrile and 0.01% formic acid (pump B), and the peptides were eluted with a linear gradient of 5-65% of pump B for 20 min at the flow rate of 2 mL/min. Data-dependent MS/MS acquisitions were performed on precursors with charge states of 2 or 3 over a survey mass range of 400-2000. Proteins were identified by searching the database of the National Center for Biotechnology Information using the ProID search engine (Applied Biosystems).
Glycosidase digestion of the MBP-ligand glycoproteins
The MBP-ligand glycoprotein fraction, which was eluted from an MBP-affinity column with HBS-C2, was concentrated by ultrafiltration as described above, and the concentrated MLGPs solution (3 μg/μL) was heated in a solution consisting of 0.1% SDS, 50 mM 2-mercaptoethanol, and 75 mM Tris-HCl buffer, pH 7.5, at 100
• C for 5 min. An aliquot of the denatured proteins dissolved in 0.5% Nonidet P-40, 2 mM EDTA, 75 mM Tris-HCl, pH 7.5, and 0.03% PMSF was digested with 0.5 U of PNGase F (New England Bio Labs) at 37
• C for 18 h. An aliquot of the denatured MBP-ligand protein solution was digested with 1.6 mU of endo H in a 100 mM citric acid-NaOH buffer, pH 5.5, and 0.03% PMSF at 37
• C for 18 h.
MBP blotting of the MLGPs and their deglycosylated forms
Deglycosylated and control samples were resolved by SDS-PAGE on a 5-20% gradient gel, and then transferred to a PVDF membrane. After blocking the membrane with TBS containing 3% skim milk, the membrane was incubated first with 5.6 μg/mL MBP purified from human serum for 2-18 h, and then with mouse anti-human serum-MBP monoclonal IgG1 (10 μg/mL, HYB131-01) for 2 h, and finally with horseradish peroxidase-conjugated goat anti-mouse IgG (H+L) (1:1600 dilution) for 1 h. Each incubation was performed at room temperature in TBS containing 10 mM CaCl 2 and 3% skim milk, followed by three washes with TBS containing 10 mM CaCl 2 and 0.05% Tween 20. The protein bands were visualized with a chemiluminescent substrate kit as described above. centrifuged at 11,000 × g for 20 min at 4
Purification of CD26 from SW1116 cell lysates
• C, and the supernatant (140 mL) was applied to an AAL column (gel volume; 3 mL) equilibrated with HBS-T1. The column was washed with HBS-T1, and then the bound glycoproteins were eluted with HBS-T2 (a fucose-containing buffer). The fractions bound to an AAL column was pooled, diluted with five times volume of HBS-T3 (a calcium-containing buffer) to reduce a fucose concentration, and applied to an MBP column (gel volume; 3 mL). The MBP affinity chromatography was performed with HBS-T3 as the loading buffer and HBS-T4 (an EDTA-containing buffer) as the eluting buffer. The eluates were then applied to an anti-human CD26 mAb-Sepharose 4B column (gel volume: 0.7 mL) equilibrated with TBS#-T1. The column was washed with TBS#-T1, and then with TBS#-T2 to reduce a Triton X-100 concentration, and the proteins bound were eluted with DEA-T. The eluates were neutralized immediately, and then concentrated by ultrafiltration as described above. The concentrated CD 26 sample (approx. 25 μg protein, as estimated on densitography of the SDS-PAGE band) was mixed with 64 μL of SDS-PAGE sample buffer consisting of 12% SDS, 188 mM Tris-HCl buffer, pH 6.8, 15% 2-mercaptoethanol, and 30% glycerol, resolved on a 5-20% polyacrylamide gradient gel, and then stained with colloidal Coomassie brilliant blue G-250. The CD26 bands migrating to around 110 kDa were excised from the gel and subjected to in-gel digestion for further analyses.
Preparation of MBP-binding and non-MBP-binding fractions from chymotrypsin-digests of the CD26 purified from SW1116
cell lysates CD26 was purified from cell lysates by means of an AAL column (gel volume: 4 mL), followed by an MBP-agarose column (gel volume: 5 mL), and then an anti-human CD26 mAb column (gel volume: 1 mL). The conditions for the AAL and MBP-affinity columns were the same as described above. The glycoproteins bound to an MBP column were applied to an anti-human CD26 mAb column equilibrated with TBS#-T1, and washed with TBS#-T2, and then with TBS#-T2 with no protease inhibitor mixture. The CD 26 bound to the column was eluted with DEA-T with no protease inhibitor mixture. The eluates were neutralized immediately with 2 M imidazole to pH 7.2. To remove Triton X-100 from the CD26 specimen (approx. 95 μg protein obtained from 70 flasks × 175 cm 2 flask (3 × 10 10 cells)), trichloroacetic acid (TCA) was added to the purified CD26 solution to a final concentration of 10%, and the suspension was left standing on ice for 15 min, and then centrifuged at 20,000 × g for 15 min at 4
• C. The precipitate was washed with 5% TCA, ethanol/0.2 M sodium acetate (8:2, v/v), and then 100% ethanol by centrifugation at 20,000 × g for 15 min at 4
• C. The washed precipitate was dried up in a desiccator over silica gel, and then subjected to reduction and alkylation. The dried CD26 was dissolved in 7 M guanidineHCl containing 0.5 M Tris-HCl, pH 8.5, and 2 mM EDTA, and then reduced by adding dithiothreitol to a final concentration of 2 mM, followed by incubation for 1 h at 50
• C under nitrogen. The reduced CD26 was then carboxamidemethylated in the presence of iodoacetamide at a final concentration of 4 mM for 30 min at room temperature in the dark. To the CD26 solution, 2.5 volumes of methanol, 0.625 volumes of chloroform, and then 1.875 volumes of distilled water were added on ice with vigorous stirring, and the solution was centrifuged at 10,000 × g for 5 min at 4
• C, and then the aqueous layer containing salts was removed. Then, to the CD26 protein present at the interface with the chloroform layer, 2.5 original sample volumes of methanol were added on ice, and after vigorous stirring, the mixture was centrifuged at 15,000 × g for 5 min at 4
• C, and the precipitated CD26 was dried up and dissolved in the 0.1 M Tris-HCl buffer, pH 8.2, containing 6 M urea. Twenty microliters of the CD26 solution in 6 M urea was mixed with 80 μL of 0.1 M Tris-HCl buffer, pH 8.2 (final concentration of urea, 1.2 M), and denatured at 100
• C for 10 min. After cooling down to room temperature, 1.9 μg of α-chymotrypsin (enzyme: substrate; 1:50 w/w) was added, and the solution was incubated at 37
• C overnight. The digestion was stopped by heating at 100
• C for 10 min, and the reaction mixture was subjected to centrifugation at 15,000 × g for 5 min at 4
• C. The resulting supernatant was separated into MBP-binding and non-MBPbinding glycopeptides on an MBP-affinity column as follows. To the chymotrypsin digest of CD26 was added an equal volume of double concentration HBS-1 (a calcium-containing buffer), and then the solution was applied to an MBP-agarose column (gel volume: 1 mL) equilibrated with HBS-1, and the column was washed with HBS-1. The MBP-binding fraction was eluted with HBS-2 (an EDTA-containing buffer). The pass-through fraction (non-MBP-binding glycopeptides) and the eluted fraction (MBP-binding glycopeptides) were each subjected to gel filtration on a Sephadex G-10 column (column size: 1 × 14 cm) for desalting, and then the column was developed with a 10 mM ammonium bicarbonate buffer, pH 8.1. Each desalted glycopeptide fraction was pooled and subjected to further analyses.
MALDI-MS analysis of the N-glycans of CD26
The excised CD26 gel band was reduced with 50 mM dithioerythritol and alkylated with 65 mM iodoacetamide in the 100 mM ammonium bicarbonate buffer, pH 8.5, followed by destaining with 50% acetonitrile in the 50 mM ammonium bicarbonate buffer, pH 8.5. The N-linked glycans were then released by incubation overnight with PNGase F (Roche Diagnostics GmbH) in the 50 mM ammonium bicarbonate buffer, pH 8.5, and additionally extracted several times with water. The N-glycans from the isolated CD26 glycopeptide fractions (the MBP-binding and non-MBP-binding chymotryptic peptides separated on passing through an MBP column) were released directly with PNGase F in the 50 mM ammonium bicarbonate buffer, pH 8.5, and separated from de-N-glycosylated peptides by passing through a reverse-phase C18 Sep-Pak cartridge. All N-glycans collected from either source were permethylated using the NaOH/DMSO slurry method as described (Dell et al. 1994) . For MALDI-TOF MS glycan profiling, the permethyl derivatives in acetonitrile were mixed 1:1 with a 2,5-dihydroxybenzoic acid (DHB) matrix (10 mg/mL in acetonitrile), spotted on the target plate, airdried, and then recrystallized on-plate with acetonitrile. Data acquisition was performed on a 4700 Proteomics Analyzer (Applied Biosystems) operated in either the linear or reflectron mode.
Analysis of de-N-glycosylated peptides by MALDI and nanoLC-ESI-MS/MS
The MBP-binding and non-MBP-binding chymotryptic peptides were de-N-glycosylated with PNGase F (Roche Diagnostics GmbH), and then passed through a C18 Sep-pak cartridge to
